Venkataraman Balasubramanian
Examiner (ID: 17374, Phone: (571)272-0662 , Office: P/1624 )
Most Active Art Unit | 1624 |
Art Unit(s) | 1624, 1611 |
Total Applications | 2999 |
Issued Applications | 2017 |
Pending Applications | 254 |
Abandoned Applications | 728 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 16998343
[patent_doc_number] => 11077125
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-03
[patent_title] => Ophthalmic composition containing sulfasalazine and hyaluronic acid
[patent_app_type] => utility
[patent_app_number] => 16/469969
[patent_app_country] => US
[patent_app_date] => 2017-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4418
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16469969
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/469969 | Ophthalmic composition containing sulfasalazine and hyaluronic acid | Dec 14, 2017 | Issued |
Array
(
[id] => 15360749
[patent_doc_number] => 20200016139
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-16
[patent_title] => PHARMACEUTICAL COMBINATION COMPRISING A T-TYPE CALCIUM CHANNEL BLOCKER
[patent_app_type] => utility
[patent_app_number] => 16/470109
[patent_app_country] => US
[patent_app_date] => 2017-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13715
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16470109
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/470109 | Pharmaceutical combination comprising a T-type calcium channel blocker | Dec 14, 2017 | Issued |
Array
(
[id] => 13457735
[patent_doc_number] => 20180280410
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-04
[patent_title] => NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES
[patent_app_type] => utility
[patent_app_number] => 15/832750
[patent_app_country] => US
[patent_app_date] => 2017-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37865
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15832750
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/832750 | NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES | Dec 4, 2017 | Abandoned |
Array
(
[id] => 12790651
[patent_doc_number] => 20180155386
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-06-07
[patent_title] => PROGESTERONE ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 15/830669
[patent_app_country] => US
[patent_app_date] => 2017-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11824
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15830669
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/830669 | PROGESTERONE ANTAGONISTS | Dec 3, 2017 | Abandoned |
Array
(
[id] => 12606570
[patent_doc_number] => 20180094020
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-04-05
[patent_title] => 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/821508
[patent_app_country] => US
[patent_app_date] => 2017-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33402
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -79
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15821508
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/821508 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | Nov 21, 2017 | Abandoned |
Array
(
[id] => 12580569
[patent_doc_number] => 20180085352
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-03-29
[patent_title] => Topical Localized Isoxazoline Formulation
[patent_app_type] => utility
[patent_app_number] => 15/819523
[patent_app_country] => US
[patent_app_date] => 2017-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9500
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15819523
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/819523 | Topical localized isoxazoline formulation | Nov 20, 2017 | Issued |
Array
(
[id] => 14867973
[patent_doc_number] => 20190284228
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-19
[patent_title] => METHOD FOR MODIFYING T CELL POPULATION
[patent_app_type] => utility
[patent_app_number] => 16/347337
[patent_app_country] => US
[patent_app_date] => 2017-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14114
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16347337
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/347337 | Method for modifying T cell population | Nov 7, 2017 | Issued |
Array
(
[id] => 12233148
[patent_doc_number] => 20180066010
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-03-08
[patent_title] => 'ISOXAZOLIDINE DERIVATIVES'
[patent_app_type] => utility
[patent_app_number] => 15/807066
[patent_app_country] => US
[patent_app_date] => 2017-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58469
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15807066
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/807066 | Isoxazolidine derivatives | Nov 7, 2017 | Issued |
Array
(
[id] => 13478973
[patent_doc_number] => 20180291029
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-11
[patent_title] => NOVEL TRICYCLIC COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 15/806104
[patent_app_country] => US
[patent_app_date] => 2017-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 90601
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15806104
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/806104 | NOVEL TRICYCLIC COMPOUNDS | Nov 6, 2017 | Abandoned |
Array
(
[id] => 16008997
[patent_doc_number] => 20200179341
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING MULTIPLE MYELOMA AND INCREASING ANTIBODY DEPENDENT CELL CYTOTOXICITY BY TARGETING THE ARYL HYDROCARBON RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 16/347524
[patent_app_country] => US
[patent_app_date] => 2017-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15879
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16347524
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/347524 | METHODS AND COMPOSITIONS FOR TREATING MULTIPLE MYELOMA AND INCREASING ANTIBODY DEPENDENT CELL CYTOTOXICITY BY TARGETING THE ARYL HYDROCARBON RECEPTOR | Nov 5, 2017 | Abandoned |
Array
(
[id] => 12204821
[patent_doc_number] => 20180050047
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-02-22
[patent_title] => 'CORTEXOLONE 17alpha-PROPIONATE FOR USE IN THE TREATMENT OF SKIN WOUNDS AND/OR ATROPHIC SKIN DISORDERS'
[patent_app_type] => utility
[patent_app_number] => 15/793011
[patent_app_country] => US
[patent_app_date] => 2017-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 12735
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15793011
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/793011 | CORTEXOLONE 17alpha-PROPIONATE FOR USE IN THE TREATMENT OF SKIN WOUNDS AND/OR ATROPHIC SKIN DISORDERS | Oct 24, 2017 | Abandoned |
Array
(
[id] => 13371685
[patent_doc_number] => 20180237383
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-23
[patent_title] => NATURAL PRODUCT ANALOGS INCLUDING AN ANTI-INFLAMMATORY CYANOENONE PHARMACORE AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 15/791677
[patent_app_country] => US
[patent_app_date] => 2017-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39834
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15791677
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/791677 | NATURAL PRODUCT ANALOGS INCLUDING AN ANTI-INFLAMMATORY CYANOENONE PHARMACORE AND METHODS OF USE | Oct 23, 2017 | Abandoned |
Array
(
[id] => 15145035
[patent_doc_number] => 20190350995
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-21
[patent_title] => THERAPEUTIC COMPOSITION DERIVED FROM ANTHOSTEMA SENEGALENSE
[patent_app_type] => utility
[patent_app_number] => 16/476192
[patent_app_country] => US
[patent_app_date] => 2017-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6556
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16476192
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/476192 | THERAPEUTIC COMPOSITION DERIVED FROM ANTHOSTEMA SENEGALENSE | Oct 19, 2017 | Abandoned |
Array
(
[id] => 14777911
[patent_doc_number] => 20190263853
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-29
[patent_title] => STRUCTURES AND MECHANISM FOR THE DESIGN OF HIGHLY POTENT GLUCOCORTICOIDS
[patent_app_type] => utility
[patent_app_number] => 16/341275
[patent_app_country] => US
[patent_app_date] => 2017-10-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17012
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 138
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16341275
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/341275 | Structures and mechanism for the design of highly potent glucocorticoids | Oct 12, 2017 | Issued |
Array
(
[id] => 12603099
[patent_doc_number] => 20180092863
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-04-05
[patent_title] => ANTICOAGULANT COMPOUNDS AND THEIR USE
[patent_app_type] => utility
[patent_app_number] => 15/730939
[patent_app_country] => US
[patent_app_date] => 2017-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8528
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15730939
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/730939 | ANTICOAGULANT COMPOUNDS AND THEIR USE | Oct 11, 2017 | Abandoned |
Array
(
[id] => 12706873
[patent_doc_number] => 20180127457
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-10
[patent_title] => NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3BETA-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVERS DISEASES AND ATHEROSCLEROSIS
[patent_app_type] => utility
[patent_app_number] => 15/728827
[patent_app_country] => US
[patent_app_date] => 2017-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9267
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15728827
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/728827 | NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3BETA-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVERS DISEASES AND ATHEROSCLEROSIS | Oct 9, 2017 | Abandoned |
Array
(
[id] => 12606564
[patent_doc_number] => 20180094018
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-04-05
[patent_title] => Progesterone Phosphate Analogs and Uses Related Thereto
[patent_app_type] => utility
[patent_app_number] => 15/728459
[patent_app_country] => US
[patent_app_date] => 2017-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20044
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15728459
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/728459 | Progesterone phosphate analogs and uses related thereto | Oct 8, 2017 | Issued |
Array
(
[id] => 15828337
[patent_doc_number] => 20200129450
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-30
[patent_title] => COMPOSITION COMPRISING OSMUNDACETONE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR PREVENTING OR TREATING BONE DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/338354
[patent_app_country] => US
[patent_app_date] => 2017-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14634
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16338354
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/338354 | COMPOSITION COMPRISING OSMUNDACETONE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR PREVENTING OR TREATING BONE DISEASE | Sep 27, 2017 | Abandoned |
Array
(
[id] => 15306357
[patent_doc_number] => 10517859
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-12-31
[patent_title] => Gel local anesthetic agent and gel local anesthetic preparation using same
[patent_app_type] => utility
[patent_app_number] => 15/712624
[patent_app_country] => US
[patent_app_date] => 2017-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7628
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15712624
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/712624 | Gel local anesthetic agent and gel local anesthetic preparation using same | Sep 21, 2017 | Issued |
Array
(
[id] => 12580503
[patent_doc_number] => 20180085330
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-03-29
[patent_title] => Dose Adjustment
[patent_app_type] => utility
[patent_app_number] => 15/713137
[patent_app_country] => US
[patent_app_date] => 2017-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5338
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15713137
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/713137 | Dose Adjustment | Sep 21, 2017 | Abandoned |